{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:07:43Z","timestamp":1791090463276,"version":"4.1.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Cilostazol is indicated for alleviating intermittent claudication (IC) in stable-phase peripheral arterial disease (PAD) patients. Conducting data mining on adverse events (AEs) of cilostazol in the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to explore its potential medication risks and advance more rational and secure clinical medication practices.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study utilized the Open Vigil 2.1-MedDRA tool to retrieve and extract AE reporting data related to cilostazol from the FAERS database spanning the first quarter of 2004 to the first quarter of 2024. The primary methodology employed was the application of the reporting odds ratio (ROR) method to detect risk signals associated with AEs of cilostazol.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 2,130 AE reports involving cilostazol were identified as the primary suspect drug, with a total of 7,134 AEs reported. These reports were predominantly concentrated among patients aged 60 and above, with a higher occurrence in males compared to females. Japan ranked first among the reporting countries, and the majority of reports were submitted by healthcare professionals. Through the screening of cilostazol, a total of 323 positive risk signals for AEs were identified, encompassing 23 system organ classes (SOCs). A comparison with the existing cilostazol product label revealed 8 AEs that were not included based on the number of AE reports, and 19 AEs that were not included based on the strength of the risk signals. Cilostazol exhibited positive risk signals for AEs primarily affecting 8 organ systems based on the SOC classification. Among these, cardiac disorders ranked highest, with a total of 53 positive risk signals for cardiovascular-related AEs identified. In terms of the number of reports, cardiac failure ranked first, aligning with the black box warning issued by the FDA regarding cilostazol. The occurrence of adverse reactions related to cilostazol is primarily concentrated within the first month of treatment. However, a certain proportion of adverse reactions have been reported to occur after long-term use (exceeding 360 days) of cilostazol therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our results have further enriched the observations from existing clinical and real-world studies, uncovering new AE signals for cilostazol, including fall, cerebral infarction, pneumonia, loss of consciousness, acute kidney injury, renal impairment, renal failure, cardiac vein perforation, basal ganglia haematoma, cerebral hyperperfusion syndrome, et al. This study also highlights the significant impact of cilostazol on the cardiovascular system, necessitating close attention to potential cardiovascular toxicities. In addition to focusing on the short-term adverse reactions following cilostazol administration, thorough research into its long-term safety profile is also imperative. This study provides recommendations and guidance for the rational and safe clinical use of cilostazol. In the future, prospective studies are needed to explore the occurrence of related AEs further.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0314957","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T18:39:28Z","timestamp":1733337568000},"page":"e0314957","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database"],"prefix":"10.1371","volume":"19","author":[{"given":"Lufeng","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5332-6327","authenticated-orcid":true,"given":"Gang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"42","key":"pone.0314957.ref001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.7748\/ns.17.42.45.s60","article-title":"Intermittent claudication","volume":"17","author":"C. Bick","year":"2003","journal-title":"Nurs Stand"},{"issue":"2","key":"pone.0314957.ref002","first-page":"163","article-title":"Intermittent claudication","volume":"173","author":"E Criado","year":"1991","journal-title":"Surg Gynecol Obstet"},{"issue":"1","key":"pone.0314957.ref003","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1517\/13543784.12.1.101","article-title":"Developing pharmaceutical treatments for peripheral artery disease","volume":"12","author":"DA Duprez","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"pone.0314957.ref004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.yasu.2023.04.009","article-title":"Current Management of Intermittent Claudication","volume":"57","author":"DP Stonko","year":"2023","journal-title":"Adv Surg"},{"issue":"12","key":"pone.0314957.ref005","first-page":"CD000990","article-title":"Exercise for intermittent claudication","volume":"12","author":"R Lane","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"pone.0314957.ref006","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1067\/mva.2002.129654","article-title":"Pharmacologic therapy for peripheral arterial disease and claudication","volume":"36","author":"WR Hiatt","year":"2002","journal-title":"J Vasc Surg"},{"issue":"2","key":"pone.0314957.ref007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00129784-200303020-00006","article-title":"Cilostazol: a review of its use in intermittent claudication","volume":"3","author":"TM Chapman","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"pone.0314957.ref008","unstructured":"Otsuka 21\u201094\u2010201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/20863.cfm (accessed May 2014)."},{"key":"pone.0314957.ref009","unstructured":"Otsuka 21\u201098\u2010214\u201001. CASTLE. A randomized, double\u2010blind, placebo\u2010controlled, multicenter, parallel\u2010arm, study to assess the long\u2010term effects of Pletal\u00ae (Cilostazol) versus placebo administered orally to patients with intermittent claudication secondary to peripheral arterial disease. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/20863.cfm (accessed May 2014)."},{"issue":"1","key":"pone.0314957.ref010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1345\/aph.19408","article-title":"Cilostazol: treatment of intermittent claudication","volume":"35","author":"MP Reilly","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"5","key":"pone.0314957.ref011","first-page":"563","article-title":"Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study","volume":"37","author":"Y Ikeda","year":"1987","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"pone.0314957.ref012","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00005344-199212000-00009","article-title":"Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture","volume":"20","author":"S Takahashi","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"issue":"12A","key":"pone.0314957.ref013","doi-asserted-by":"crossref","first-page":"28D","DOI":"10.1016\/S0002-9149(01)01719-2","article-title":"Analysis of the cilostazol safety database","volume":"87","author":"CM Pratt","year":"2001","journal-title":"Am J Cardiol"},{"key":"pone.0314957.ref014","doi-asserted-by":"crossref","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"F Zou","year":"2023","journal-title":"Front Pharmacol"},{"issue":"2","key":"pone.0314957.ref015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"RJ Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"pone.0314957.ref016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0018578718795271","article-title":"The Newly Available FAERS Public Dashboard: Implications for Health Care Professionals","volume":"54","author":"A. Kumar","year":"2019","journal-title":"Hosp Pharm"},{"issue":"7","key":"pone.0314957.ref017","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"pone.0314957.ref018","doi-asserted-by":"crossref","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System","volume":"13","author":"Y Shu","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0314957.ref019","doi-asserted-by":"crossref","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","article-title":"Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS","volume":"13","author":"S Tang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0314957.ref020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"15","key":"pone.0314957.ref021","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1517\/14656566.9.15.2683","article-title":"Cilostazol and peripheral arterial disease","volume":"9","author":"L Pearce","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"26","key":"pone.0314957.ref022","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.2174\/092986710792065018","article-title":"Regulators of platelet cAMP levels: clinical and therapeutic implications","volume":"17","author":"L No\u00e9","year":"2010","journal-title":"Curr Med Chem"},{"issue":"6","key":"pone.0314957.ref023","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/pds.4167","article-title":"Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany","volume":"26","author":"J Castellsague","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"pone.0314957.ref024","first-page":"CD003748","article-title":"Cilostazol for intermittent claudication","volume":"2014","author":"R Bedenis","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0314957.ref025","unstructured":"Product Information: PLETAL(R) oral tablets, cilostazol oral tablets. Otsuka America Pharmaceutical, Inc. (per FDA), Rockville, MD, 2015."},{"key":"pone.0314957.ref026","unstructured":"Pletal. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020863s021lbl.pdf. Accessed 2\/5\/2021."},{"issue":"100","key":"pone.0314957.ref027","first-page":"56","article-title":"Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks","volume":"18","year":"2009","journal-title":"Prescrire Int"},{"issue":"7","key":"pone.0314957.ref028","first-page":"1580","article-title":"Dual Antiplatelet Therapy: A Concise Review for Clinicians","volume":"13","author":"HUH Virk","year":"2023","journal-title":"Life (Basel)"},{"issue":"5","key":"pone.0314957.ref029","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.nefroe.2021.06.007","article-title":"Cilostazol: Several issues to be considered about the safety profile","volume":"43","author":"H. Ito","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"issue":"2","key":"pone.0314957.ref030","first-page":"305","article-title":"Cyclic AMP and the pathogenesis of myocardial injury","volume":"27","author":"JC Lee","year":"1980","journal-title":"Res Commun Chem Pathol Pharmacol"},{"issue":"3","key":"pone.0314957.ref031","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.2042-7158.1971.tb08642.x","article-title":"The role of cyclic AMP in isoprenaline-induced cardiac necroses in the rat","volume":"23","author":"PA Martorana","year":"1971","journal-title":"J Pharm Pharmacol"},{"issue":"7955","key":"pone.0314957.ref032","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(76)90090-8","article-title":"Cyclic adenosine monophosphate, ventricular fibrillation, and antiarrhythmic drugs","volume":"1","author":"T Podzuweit","year":"1976","journal-title":"Lancet"},{"issue":"11","key":"pone.0314957.ref033","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM198903163201101","article-title":"A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure","volume":"320","author":"R DiBianco","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0314957.ref034","doi-asserted-by":"crossref","first-page":"41A","DOI":"10.1016\/0002-9149(89)90392-5","article-title":"Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure","volume":"63","author":"M. Packer","year":"1989","journal-title":"Am J Cardiol"},{"key":"pone.0314957.ref035","unstructured":"European medicines agency recommends restricting use of cilostazol-containing medicines. European Medicines Agency. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_en.pdf."},{"issue":"2","key":"pone.0314957.ref036","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects)","volume":"47","author":"WR Hiatt","year":"2008","journal-title":"J Vasc Surg"},{"issue":"Suppl 2","key":"pone.0314957.ref037","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00003088-199937002-00003","article-title":"Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol","volume":"37","author":"SL Bramer","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 2","key":"pone.0314957.ref038","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003088-199937002-00004","article-title":"Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites","volume":"37","author":"S Mallikaarjun","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 2","key":"pone.0314957.ref039","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-199937002-00007","article-title":"Effects of CYP3A inhibition on the metabolism of cilostazol","volume":"37","author":"A Suri","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"pone.0314957.ref040","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10557-021-07187-x","article-title":"Cilostazol: a Review of Basic Mechanisms and Clinical Uses","volume":"36","author":"RY Kherallah","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"pone.0314957.ref041","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.phrs.2006.10.010","article-title":"Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia\/reoxygenation","volume":"55","author":"H Torii","year":"2007","journal-title":"Pharmacol Res"},{"issue":"2","key":"pone.0314957.ref042","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lfs.2014.06.017","article-title":"Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats","volume":"110","author":"K Takeuchi","year":"2014","journal-title":"Life Sci"},{"issue":"3","key":"pone.0314957.ref043","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/gutjnl-2019-319926","article-title":"Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score","volume":"70","author":"W Hatta","year":"2021","journal-title":"Gut"},{"issue":"1","key":"pone.0314957.ref044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40801-021-00268-1","article-title":"Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"C Teng","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"pone.0314957.ref045","doi-asserted-by":"crossref","first-page":"1280490","DOI":"10.3389\/fphar.2023.1280490","article-title":"A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system","volume":"14","author":"H Li","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0314957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T18:39:44Z","timestamp":1733337584000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0314957"}},"subtitle":[],"editor":[{"given":"Ahmed Qasim Mohammed","family":"Alhatemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0314957","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]}}}